# Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

> **NCT06905509** · PHASE2 · RECRUITING · sponsor: **Joseph Tuscano** · enrollment: 25 (estimated)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carboplatin
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Etoposide Phosphate
- **DRUG:** Gemcitabine
- **DRUG:** Ifosfamide
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Oxaliplatin
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT06905509
- **Lead sponsor:** Joseph Tuscano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905509, "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06905509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*